Comirnaty

Overview

The mRNA COVID-19 vaccine (BNT162b2 / tozinameran) co-developed and commercialized with Pfizer - the first mRNA vaccine authorized for human use and the product that validated the platform at global scale.

Marketed globally as an updated seasonal COVID-19 vaccine; the XFG-adapted formulation is now authorized in both the EU (July 29, 2026) and the US (FDA approval August 27, 2026, for adults 65+ and higher-risk 5-64 year-olds). Still BioNTech's primary revenue driver, but sales have collapsed faster than guided - Q2 2026 revenue was just €105.6M - driving the August 2026 guidance cut and the manufacturing-network pullback.

Key Specs